# Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

> **NCT05092451** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 80 (estimated)

## Conditions studied

- B-Cell Lymphoma
- Myelodysplastic Syndromes (MDS)
- Acute Myeloid Leukemia (AML)
- Multiple Myeloma
- Plasma Cell Leukemia
- Hodgkin Lymphoma
- T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia
- Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia
- Blastic Transformation of Chronic Myeloid Leukemia
- Germ Cell Tumors

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** CAR.70/IL15-transduced CB-NK cells
- **DRUG:** Fludarabine phosphate

## Key facts

- **NCT ID:** NCT05092451
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05092451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05092451, "Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05092451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*